Board Committees

Audit Committee Position

Phil Gutry

Mr. Phillip Gutry has served as an independent director on our Board since April 2015. He has over 20 years of experience in the biopharmaceutical industry in a variety of senior investment, business development, and strategic roles.  Mr. Gutry currently serves as chief business officer, head of finance & investor relations at Graphite Bio. Mr. Gutry brings to this role extensive business development, strategy, finance and investor relations experience with a successful track record of raising capital and establishing partnerships for biotech companies.  Mr. Gutry most recently worked at Kronos Bio, a clinical-stage oncology company focused on targeting dysregulated transcription, where he served as chief business officer. In this role, he led the acquisition of Gilead’s spleen tyrosine kinase inhibitor portfolio, which transformed Kronos into a clinical-stage company and was the primary catalyst for raising $500M in equity capital, including the company’s Initial Public Offering. Previously, Mr. Gutry served in senior business development and finance roles at Regeneron Pharmaceuticals, MPM Capital and Gilead Sciences during which he led or managed over 30 transactions raising over $2 billion in equity, debt, and R&D funding. Mr. Gutry received his A.B. in Earth Sciences from Dartmouth College and his M.B.A. in Healthcare Management from The Wharton School.

Chair

Magnus Persson, M.D., Ph.D.

Dr. Persson has served as an independent director on our Board since August 2012. Dr. Persson is currently serving as CEO of Karolinska Institutet Holding AB in Stockholm, Sweden. He has also served as an Associate Professor in Physiology at Karolinska Institutet since September 1994. Dr. Persson has served as a practicing pediatrician at CityAkuten in Stockholm, Sweden, since December 2012. Dr. Persson served as a Partner at HealthCap, a Swedish-based venture capital firm from January 2008 through December 2009, and as a Managing Partner at The Column Group, a San Francisco based venture capital firm, from January 2010 through November 2011. Dr. Persson co-founded Aerocrine AB, a medical technology company in 1994. Dr. Persson has also served on the boards of Karolinska Institutet Innovations AB, a technology transfer company, since December 2011, Galecto AB, a biotechnology company, since January 2013, AscendxSpine Inc., a medical device company, since December 2012, SLS Ventures AB, a life science venture capital firm since March 2012, Karolinska Institutet Information AB, a healthcare IT-software company since October 2015, Immunicum AB a biotechnology company since December 2015, and Albumedix AS, a biotechnology company since January 2016. Dr. Persson received his M.D. and Ph.D. in physiology from Karolinska Institutet.

Member

Dr. Suzanne Bruhn

Dr. Bruhn brings to the Company her extensive experience in the biopharmaceutical industry, including her expertise in the development, commercialization and partnering of products for the treatments of serious and rare diseases. Dr. Bruhn currently serves as the President, CEO and as a director of Tiaki Therapeutics. Prior to that, she has served as the President and CEO, and as a director of Proclara Biosciences and previously at Promedior. Dr. Bruhn currently serves on the board of directors of Aeglea BioTherapeutics, Retrophin and Pliant Therapeutics. Dr. Bruhn received her B.S. degree in Chemistry from Iowa State University and her Ph.D. in Chemistry from Massachusetts Institute of Technology. Dr. Bruhn was appointed as an independent director on our Board in April 2020.

Member

Audit Committee Charter

Download

Phil Gutry

Mr. Phillip Gutry has served as an independent director on our Board since April 2015. He has over 20 years of experience in the biopharmaceutical industry in a variety of senior investment, business development, and strategic roles.  Mr. Gutry currently serves as chief business officer, head of finance & investor relations at Graphite Bio. Mr. Gutry brings to this role extensive business development, strategy, finance and investor relations experience with a successful track record of raising capital and establishing partnerships for biotech companies.  Mr. Gutry most recently worked at Kronos Bio, a clinical-stage oncology company focused on targeting dysregulated transcription, where he served as chief business officer. In this role, he led the acquisition of Gilead’s spleen tyrosine kinase inhibitor portfolio, which transformed Kronos into a clinical-stage company and was the primary catalyst for raising $500M in equity capital, including the company’s Initial Public Offering. Previously, Mr. Gutry served in senior business development and finance roles at Regeneron Pharmaceuticals, MPM Capital and Gilead Sciences during which he led or managed over 30 transactions raising over $2 billion in equity, debt, and R&D funding. Mr. Gutry received his A.B. in Earth Sciences from Dartmouth College and his M.B.A. in Healthcare Management from The Wharton School.

Magnus Persson, M.D., Ph.D.

Dr. Persson has served as an independent director on our Board since August 2012. Dr. Persson is currently serving as CEO of Karolinska Institutet Holding AB in Stockholm, Sweden. He has also served as an Associate Professor in Physiology at Karolinska Institutet since September 1994. Dr. Persson has served as a practicing pediatrician at CityAkuten in Stockholm, Sweden, since December 2012. Dr. Persson served as a Partner at HealthCap, a Swedish-based venture capital firm from January 2008 through December 2009, and as a Managing Partner at The Column Group, a San Francisco based venture capital firm, from January 2010 through November 2011. Dr. Persson co-founded Aerocrine AB, a medical technology company in 1994. Dr. Persson has also served on the boards of Karolinska Institutet Innovations AB, a technology transfer company, since December 2011, Galecto AB, a biotechnology company, since January 2013, AscendxSpine Inc., a medical device company, since December 2012, SLS Ventures AB, a life science venture capital firm since March 2012, Karolinska Institutet Information AB, a healthcare IT-software company since October 2015, Immunicum AB a biotechnology company since December 2015, and Albumedix AS, a biotechnology company since January 2016. Dr. Persson received his M.D. and Ph.D. in physiology from Karolinska Institutet.

Dr. Suzanne Bruhn

Dr. Bruhn brings to the Company her extensive experience in the biopharmaceutical industry, including her expertise in the development, commercialization and partnering of products for the treatments of serious and rare diseases. Dr. Bruhn currently serves as the President, CEO and as a director of Tiaki Therapeutics. Prior to that, she has served as the President and CEO, and as a director of Proclara Biosciences and previously at Promedior. Dr. Bruhn currently serves on the board of directors of Aeglea BioTherapeutics, Retrophin and Pliant Therapeutics. Dr. Bruhn received her B.S. degree in Chemistry from Iowa State University and her Ph.D. in Chemistry from Massachusetts Institute of Technology. Dr. Bruhn was appointed as an independent director on our Board in April 2020.

Compensation Committee Position

Magnus Persson, M.D., Ph.D.

Dr. Persson has served as an independent director on our Board since August 2012. Dr. Persson is currently serving as CEO of Karolinska Institutet Holding AB in Stockholm, Sweden. He has also served as an Associate Professor in Physiology at Karolinska Institutet since September 1994. Dr. Persson has served as a practicing pediatrician at CityAkuten in Stockholm, Sweden, since December 2012. Dr. Persson served as a Partner at HealthCap, a Swedish-based venture capital firm from January 2008 through December 2009, and as a Managing Partner at The Column Group, a San Francisco based venture capital firm, from January 2010 through November 2011. Dr. Persson co-founded Aerocrine AB, a medical technology company in 1994. Dr. Persson has also served on the boards of Karolinska Institutet Innovations AB, a technology transfer company, since December 2011, Galecto AB, a biotechnology company, since January 2013, AscendxSpine Inc., a medical device company, since December 2012, SLS Ventures AB, a life science venture capital firm since March 2012, Karolinska Institutet Information AB, a healthcare IT-software company since October 2015, Immunicum AB a biotechnology company since December 2015, and Albumedix AS, a biotechnology company since January 2016. Dr. Persson received his M.D. and Ph.D. in physiology from Karolinska Institutet.

Chair

Phil Gutry

Mr. Phillip Gutry has served as an independent director on our Board since April 2015. He has over 20 years of experience in the biopharmaceutical industry in a variety of senior investment, business development, and strategic roles.  Mr. Gutry currently serves as chief business officer, head of finance & investor relations at Graphite Bio. Mr. Gutry brings to this role extensive business development, strategy, finance and investor relations experience with a successful track record of raising capital and establishing partnerships for biotech companies.  Mr. Gutry most recently worked at Kronos Bio, a clinical-stage oncology company focused on targeting dysregulated transcription, where he served as chief business officer. In this role, he led the acquisition of Gilead’s spleen tyrosine kinase inhibitor portfolio, which transformed Kronos into a clinical-stage company and was the primary catalyst for raising $500M in equity capital, including the company’s Initial Public Offering. Previously, Mr. Gutry served in senior business development and finance roles at Regeneron Pharmaceuticals, MPM Capital and Gilead Sciences during which he led or managed over 30 transactions raising over $2 billion in equity, debt, and R&D funding. Mr. Gutry received his A.B. in Earth Sciences from Dartmouth College and his M.B.A. in Healthcare Management from The Wharton School.

Member

Dr. Suzanne Bruhn

Dr. Bruhn brings to the Company her extensive experience in the biopharmaceutical industry, including her expertise in the development, commercialization and partnering of products for the treatments of serious and rare diseases. Dr. Bruhn currently serves as the President, CEO and as a director of Tiaki Therapeutics. Prior to that, she has served as the President and CEO, and as a director of Proclara Biosciences and previously at Promedior. Dr. Bruhn currently serves on the board of directors of Aeglea BioTherapeutics, Retrophin and Pliant Therapeutics. Dr. Bruhn received her B.S. degree in Chemistry from Iowa State University and her Ph.D. in Chemistry from Massachusetts Institute of Technology. Dr. Bruhn was appointed as an independent director on our Board in April 2020.

Member

Compensation Committee Charter

Download

Magnus Persson, M.D., Ph.D.

Dr. Persson has served as an independent director on our Board since August 2012. Dr. Persson is currently serving as CEO of Karolinska Institutet Holding AB in Stockholm, Sweden. He has also served as an Associate Professor in Physiology at Karolinska Institutet since September 1994. Dr. Persson has served as a practicing pediatrician at CityAkuten in Stockholm, Sweden, since December 2012. Dr. Persson served as a Partner at HealthCap, a Swedish-based venture capital firm from January 2008 through December 2009, and as a Managing Partner at The Column Group, a San Francisco based venture capital firm, from January 2010 through November 2011. Dr. Persson co-founded Aerocrine AB, a medical technology company in 1994. Dr. Persson has also served on the boards of Karolinska Institutet Innovations AB, a technology transfer company, since December 2011, Galecto AB, a biotechnology company, since January 2013, AscendxSpine Inc., a medical device company, since December 2012, SLS Ventures AB, a life science venture capital firm since March 2012, Karolinska Institutet Information AB, a healthcare IT-software company since October 2015, Immunicum AB a biotechnology company since December 2015, and Albumedix AS, a biotechnology company since January 2016. Dr. Persson received his M.D. and Ph.D. in physiology from Karolinska Institutet.

Phil Gutry

Mr. Phillip Gutry has served as an independent director on our Board since April 2015. He has over 20 years of experience in the biopharmaceutical industry in a variety of senior investment, business development, and strategic roles.  Mr. Gutry currently serves as chief business officer, head of finance & investor relations at Graphite Bio. Mr. Gutry brings to this role extensive business development, strategy, finance and investor relations experience with a successful track record of raising capital and establishing partnerships for biotech companies.  Mr. Gutry most recently worked at Kronos Bio, a clinical-stage oncology company focused on targeting dysregulated transcription, where he served as chief business officer. In this role, he led the acquisition of Gilead’s spleen tyrosine kinase inhibitor portfolio, which transformed Kronos into a clinical-stage company and was the primary catalyst for raising $500M in equity capital, including the company’s Initial Public Offering. Previously, Mr. Gutry served in senior business development and finance roles at Regeneron Pharmaceuticals, MPM Capital and Gilead Sciences during which he led or managed over 30 transactions raising over $2 billion in equity, debt, and R&D funding. Mr. Gutry received his A.B. in Earth Sciences from Dartmouth College and his M.B.A. in Healthcare Management from The Wharton School.

Dr. Suzanne Bruhn

Dr. Bruhn brings to the Company her extensive experience in the biopharmaceutical industry, including her expertise in the development, commercialization and partnering of products for the treatments of serious and rare diseases. Dr. Bruhn currently serves as the President, CEO and as a director of Tiaki Therapeutics. Prior to that, she has served as the President and CEO, and as a director of Proclara Biosciences and previously at Promedior. Dr. Bruhn currently serves on the board of directors of Aeglea BioTherapeutics, Retrophin and Pliant Therapeutics. Dr. Bruhn received her B.S. degree in Chemistry from Iowa State University and her Ph.D. in Chemistry from Massachusetts Institute of Technology. Dr. Bruhn was appointed as an independent director on our Board in April 2020.

Nominating and Corporate Governance Committee Position

Phil Gutry

Mr. Phillip Gutry has served as an independent director on our Board since April 2015. He has over 20 years of experience in the biopharmaceutical industry in a variety of senior investment, business development, and strategic roles.  Mr. Gutry currently serves as chief business officer, head of finance & investor relations at Graphite Bio. Mr. Gutry brings to this role extensive business development, strategy, finance and investor relations experience with a successful track record of raising capital and establishing partnerships for biotech companies.  Mr. Gutry most recently worked at Kronos Bio, a clinical-stage oncology company focused on targeting dysregulated transcription, where he served as chief business officer. In this role, he led the acquisition of Gilead’s spleen tyrosine kinase inhibitor portfolio, which transformed Kronos into a clinical-stage company and was the primary catalyst for raising $500M in equity capital, including the company’s Initial Public Offering. Previously, Mr. Gutry served in senior business development and finance roles at Regeneron Pharmaceuticals, MPM Capital and Gilead Sciences during which he led or managed over 30 transactions raising over $2 billion in equity, debt, and R&D funding. Mr. Gutry received his A.B. in Earth Sciences from Dartmouth College and his M.B.A. in Healthcare Management from The Wharton School.

Chair

Steven J. Boyd

Mr. Boyd is the Chief Investment Officer of Armistice Capital. He founded Armistice in 2012, which was named "best new hedge fund" by Hedge Funds Review the following year. Prior to Armistice, Mr. Boyd had been an analyst at Senator Investment Group and York Capital. He started his career at McKinsey & Company. Mr. Boyd received a B.S. in Economics as well as a B.A. in Political Science from The Wharton School of the University of Pennsylvania.

Member

Magnus Persson, M.D., Ph.D.

Dr. Persson has served as an independent director on our Board since August 2012. Dr. Persson is currently serving as CEO of Karolinska Institutet Holding AB in Stockholm, Sweden. He has also served as an Associate Professor in Physiology at Karolinska Institutet since September 1994. Dr. Persson has served as a practicing pediatrician at CityAkuten in Stockholm, Sweden, since December 2012. Dr. Persson served as a Partner at HealthCap, a Swedish-based venture capital firm from January 2008 through December 2009, and as a Managing Partner at The Column Group, a San Francisco based venture capital firm, from January 2010 through November 2011. Dr. Persson co-founded Aerocrine AB, a medical technology company in 1994. Dr. Persson has also served on the boards of Karolinska Institutet Innovations AB, a technology transfer company, since December 2011, Galecto AB, a biotechnology company, since January 2013, AscendxSpine Inc., a medical device company, since December 2012, SLS Ventures AB, a life science venture capital firm since March 2012, Karolinska Institutet Information AB, a healthcare IT-software company since October 2015, Immunicum AB a biotechnology company since December 2015, and Albumedix AS, a biotechnology company since January 2016. Dr. Persson received his M.D. and Ph.D. in physiology from Karolinska Institutet.

Member

Nominating and Corporate Governance Committee Charter

Download

Phil Gutry

Mr. Phillip Gutry has served as an independent director on our Board since April 2015. He has over 20 years of experience in the biopharmaceutical industry in a variety of senior investment, business development, and strategic roles.  Mr. Gutry currently serves as chief business officer, head of finance & investor relations at Graphite Bio. Mr. Gutry brings to this role extensive business development, strategy, finance and investor relations experience with a successful track record of raising capital and establishing partnerships for biotech companies.  Mr. Gutry most recently worked at Kronos Bio, a clinical-stage oncology company focused on targeting dysregulated transcription, where he served as chief business officer. In this role, he led the acquisition of Gilead’s spleen tyrosine kinase inhibitor portfolio, which transformed Kronos into a clinical-stage company and was the primary catalyst for raising $500M in equity capital, including the company’s Initial Public Offering. Previously, Mr. Gutry served in senior business development and finance roles at Regeneron Pharmaceuticals, MPM Capital and Gilead Sciences during which he led or managed over 30 transactions raising over $2 billion in equity, debt, and R&D funding. Mr. Gutry received his A.B. in Earth Sciences from Dartmouth College and his M.B.A. in Healthcare Management from The Wharton School.

Steven J. Boyd

Mr. Boyd is the Chief Investment Officer of Armistice Capital. He founded Armistice in 2012, which was named "best new hedge fund" by Hedge Funds Review the following year. Prior to Armistice, Mr. Boyd had been an analyst at Senator Investment Group and York Capital. He started his career at McKinsey & Company. Mr. Boyd received a B.S. in Economics as well as a B.A. in Political Science from The Wharton School of the University of Pennsylvania.

Magnus Persson, M.D., Ph.D.

Dr. Persson has served as an independent director on our Board since August 2012. Dr. Persson is currently serving as CEO of Karolinska Institutet Holding AB in Stockholm, Sweden. He has also served as an Associate Professor in Physiology at Karolinska Institutet since September 1994. Dr. Persson has served as a practicing pediatrician at CityAkuten in Stockholm, Sweden, since December 2012. Dr. Persson served as a Partner at HealthCap, a Swedish-based venture capital firm from January 2008 through December 2009, and as a Managing Partner at The Column Group, a San Francisco based venture capital firm, from January 2010 through November 2011. Dr. Persson co-founded Aerocrine AB, a medical technology company in 1994. Dr. Persson has also served on the boards of Karolinska Institutet Innovations AB, a technology transfer company, since December 2011, Galecto AB, a biotechnology company, since January 2013, AscendxSpine Inc., a medical device company, since December 2012, SLS Ventures AB, a life science venture capital firm since March 2012, Karolinska Institutet Information AB, a healthcare IT-software company since October 2015, Immunicum AB a biotechnology company since December 2015, and Albumedix AS, a biotechnology company since January 2016. Dr. Persson received his M.D. and Ph.D. in physiology from Karolinska Institutet.

Science and Technology Committee Position

Dr. Gilla Kaplan, Ph.D.

Gilla Kaplan is recognized as an authority on various aspects of the host immune response to mycobacterial pathogens, including the causative agents of leprosy and tuberculosis. Most recently, she was the director of the Global Health Tuberculosis program at the Bill & Melinda Gates Foundation from January 2014 to April 2018. Her scientific work has encompassed developing a deep, holistic understanding of the cellular immune response and how to harness it for host adjunctive therapies. She spent her career as an academic research scientist leading her laboratory in investigations focusing on human disease control. Building on her research experience at Rockefeller University in New York City (for 20 years) and then at the Public Health Research Institute Center at the University of Medicine and Dentistry of New Jersey in Newark (for 10 years), she led the reshaping of the TB program at the BMGF. Dr. Kaplan is the recipient of multiple grants from the NIH-NIAID and other funding organizations for her research. Dr. Kaplan served on the Board of Directors at Celgene from 1998 to 2018 and is currently a member of Tyra Biociences, Inc. Board of Directors. Dr. Kaplan received her BSc from the Hebrew University in Jerusalem Israel and her MSc and PhD from Tromso University Norway. Dr. Kaplan was appointed as an independent director on our Board in October 2020.

Chair

Dr. Sol J. Barer

Chairman of the Board

Dr. Barer spent most of his professional career with the Celgene Corporation. He was Chairman from January 2011 until June 2011, Executive Chairman from June 2010 until Jan 2011 and Chairman and Chief Executive Officer from May 2006 until June 2010. Previously he was appointed President in 1993 and Chief Operating Officer in 1994 before assuming the CEO position. He also served as Senior Vice President, Science and Technology, and Vice President/General Manager, Chiral Products, from October 1990 to October 1993, and Vice President, Technology, from September 1987 to October 1990. Dr. Barer was the founder of the biotechnology group at the Celanese Research Company which was subsequently spun out to form Celgene.

Dr. Barer currently serves as Chairman of the Board of the public companies Teva Pharmaceutical Industries, Cerecor and NexImmune, is Lead Director of ContraFect and is Chair of the private company Centrexion and a Director of 3D Biotherapeutics. He is the Founding Chair of the Hackensack Meridian Health Center for Discovery and Innovation. He is a Founder of MIG, an organization dedicated to helping Israeli biotech entrepreneurs and is a Venture Advisor to the Israel Biotechnology Fund as well as an advisor to biopharma companies.

In 2011 Dr. Barer was Chairman of the University of Medicine and Dentistry of New Jersey Governor’s Advisory Committee which resulted in sweeping changes in the structure of New Jersey’s medical schools and public research universities. He previously served as a Commissioner of the NJ Commission on Science and Technology. He was a member of the Board of Trustees of Rutgers University (until 2013). He also served two terms as Chair of the Board of Trustees of BioNJ (2010-2012) the New Jersey biotechnology organization.

Dr. Barer was named to the “Worldview 100” (Scientific American’s 100 most influential figures in today’s world of biotechnology) in 2015, named one of “25 Leadership Legends of NJ” (NJBiz) in 2012, “The 50 Most Powerful People in N.J. Health Care,” in 2012, inducted into the NJBiz Hall of Fame in 2011 and was named as one of NJ’s top 10 scientists by New Jersey Business in 2008.

Member

Magnus Persson, M.D., Ph.D.

Dr. Persson has served as an independent director on our Board since August 2012. Dr. Persson is currently serving as CEO of Karolinska Institutet Holding AB in Stockholm, Sweden. He has also served as an Associate Professor in Physiology at Karolinska Institutet since September 1994. Dr. Persson has served as a practicing pediatrician at CityAkuten in Stockholm, Sweden, since December 2012. Dr. Persson served as a Partner at HealthCap, a Swedish-based venture capital firm from January 2008 through December 2009, and as a Managing Partner at The Column Group, a San Francisco based venture capital firm, from January 2010 through November 2011. Dr. Persson co-founded Aerocrine AB, a medical technology company in 1994. Dr. Persson has also served on the boards of Karolinska Institutet Innovations AB, a technology transfer company, since December 2011, Galecto AB, a biotechnology company, since January 2013, AscendxSpine Inc., a medical device company, since December 2012, SLS Ventures AB, a life science venture capital firm since March 2012, Karolinska Institutet Information AB, a healthcare IT-software company since October 2015, Immunicum AB a biotechnology company since December 2015, and Albumedix AS, a biotechnology company since January 2016. Dr. Persson received his M.D. and Ph.D. in physiology from Karolinska Institutet.

Member

Dr. Suzanne Bruhn

Dr. Bruhn brings to the Company her extensive experience in the biopharmaceutical industry, including her expertise in the development, commercialization and partnering of products for the treatments of serious and rare diseases. Dr. Bruhn currently serves as the President, CEO and as a director of Tiaki Therapeutics. Prior to that, she has served as the President and CEO, and as a director of Proclara Biosciences and previously at Promedior. Dr. Bruhn currently serves on the board of directors of Aeglea BioTherapeutics, Retrophin and Pliant Therapeutics. Dr. Bruhn received her B.S. degree in Chemistry from Iowa State University and her Ph.D. in Chemistry from Massachusetts Institute of Technology. Dr. Bruhn was appointed as an independent director on our Board in April 2020.

Member

Science and Technology Committee Charter

Download

Dr. Gilla Kaplan, Ph.D.

Gilla Kaplan is recognized as an authority on various aspects of the host immune response to mycobacterial pathogens, including the causative agents of leprosy and tuberculosis. Most recently, she was the director of the Global Health Tuberculosis program at the Bill & Melinda Gates Foundation from January 2014 to April 2018. Her scientific work has encompassed developing a deep, holistic understanding of the cellular immune response and how to harness it for host adjunctive therapies. She spent her career as an academic research scientist leading her laboratory in investigations focusing on human disease control. Building on her research experience at Rockefeller University in New York City (for 20 years) and then at the Public Health Research Institute Center at the University of Medicine and Dentistry of New Jersey in Newark (for 10 years), she led the reshaping of the TB program at the BMGF. Dr. Kaplan is the recipient of multiple grants from the NIH-NIAID and other funding organizations for her research. Dr. Kaplan served on the Board of Directors at Celgene from 1998 to 2018 and is currently a member of Tyra Biociences, Inc. Board of Directors. Dr. Kaplan received her BSc from the Hebrew University in Jerusalem Israel and her MSc and PhD from Tromso University Norway. Dr. Kaplan was appointed as an independent director on our Board in October 2020.

Dr. Sol J. Barer

Chairman of the Board

Dr. Barer spent most of his professional career with the Celgene Corporation. He was Chairman from January 2011 until June 2011, Executive Chairman from June 2010 until Jan 2011 and Chairman and Chief Executive Officer from May 2006 until June 2010. Previously he was appointed President in 1993 and Chief Operating Officer in 1994 before assuming the CEO position. He also served as Senior Vice President, Science and Technology, and Vice President/General Manager, Chiral Products, from October 1990 to October 1993, and Vice President, Technology, from September 1987 to October 1990. Dr. Barer was the founder of the biotechnology group at the Celanese Research Company which was subsequently spun out to form Celgene.

Dr. Barer currently serves as Chairman of the Board of the public companies Teva Pharmaceutical Industries, Cerecor and NexImmune, is Lead Director of ContraFect and is Chair of the private company Centrexion and a Director of 3D Biotherapeutics. He is the Founding Chair of the Hackensack Meridian Health Center for Discovery and Innovation. He is a Founder of MIG, an organization dedicated to helping Israeli biotech entrepreneurs and is a Venture Advisor to the Israel Biotechnology Fund as well as an advisor to biopharma companies.

In 2011 Dr. Barer was Chairman of the University of Medicine and Dentistry of New Jersey Governor’s Advisory Committee which resulted in sweeping changes in the structure of New Jersey’s medical schools and public research universities. He previously served as a Commissioner of the NJ Commission on Science and Technology. He was a member of the Board of Trustees of Rutgers University (until 2013). He also served two terms as Chair of the Board of Trustees of BioNJ (2010-2012) the New Jersey biotechnology organization.

Dr. Barer was named to the “Worldview 100” (Scientific American’s 100 most influential figures in today’s world of biotechnology) in 2015, named one of “25 Leadership Legends of NJ” (NJBiz) in 2012, “The 50 Most Powerful People in N.J. Health Care,” in 2012, inducted into the NJBiz Hall of Fame in 2011 and was named as one of NJ’s top 10 scientists by New Jersey Business in 2008.

Magnus Persson, M.D., Ph.D.

Dr. Persson has served as an independent director on our Board since August 2012. Dr. Persson is currently serving as CEO of Karolinska Institutet Holding AB in Stockholm, Sweden. He has also served as an Associate Professor in Physiology at Karolinska Institutet since September 1994. Dr. Persson has served as a practicing pediatrician at CityAkuten in Stockholm, Sweden, since December 2012. Dr. Persson served as a Partner at HealthCap, a Swedish-based venture capital firm from January 2008 through December 2009, and as a Managing Partner at The Column Group, a San Francisco based venture capital firm, from January 2010 through November 2011. Dr. Persson co-founded Aerocrine AB, a medical technology company in 1994. Dr. Persson has also served on the boards of Karolinska Institutet Innovations AB, a technology transfer company, since December 2011, Galecto AB, a biotechnology company, since January 2013, AscendxSpine Inc., a medical device company, since December 2012, SLS Ventures AB, a life science venture capital firm since March 2012, Karolinska Institutet Information AB, a healthcare IT-software company since October 2015, Immunicum AB a biotechnology company since December 2015, and Albumedix AS, a biotechnology company since January 2016. Dr. Persson received his M.D. and Ph.D. in physiology from Karolinska Institutet.

Dr. Suzanne Bruhn

Dr. Bruhn brings to the Company her extensive experience in the biopharmaceutical industry, including her expertise in the development, commercialization and partnering of products for the treatments of serious and rare diseases. Dr. Bruhn currently serves as the President, CEO and as a director of Tiaki Therapeutics. Prior to that, she has served as the President and CEO, and as a director of Proclara Biosciences and previously at Promedior. Dr. Bruhn currently serves on the board of directors of Aeglea BioTherapeutics, Retrophin and Pliant Therapeutics. Dr. Bruhn received her B.S. degree in Chemistry from Iowa State University and her Ph.D. in Chemistry from Massachusetts Institute of Technology. Dr. Bruhn was appointed as an independent director on our Board in April 2020.